Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Interest & Investment Income: 2019-2025

Historic Interest & Investment Income for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to $6.2 million.

  • BridgeBio Pharma's Interest & Investment Income rose 89.29% to $6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.2 million, marking a year-over-year increase of 11.36%. This contributed to the annual value of $17.2 million for FY2024, which is 4.37% down from last year.
  • Latest data reveals that BridgeBio Pharma reported Interest & Investment Income of $6.2 million as of Q3 2025, which was up 60.06% from $3.9 million recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Interest & Investment Income registered a high of $6.2 million during Q3 2025, and its lowest value of $182,000 during Q4 2021.
  • Its 3-year average for Interest & Investment Income is $4.6 million, with a median of $4.5 million in 2023.
  • As far as peak fluctuations go, BridgeBio Pharma's Interest & Investment Income tumbled by 79.70% in 2021, and later spiked by 2,148.35% in 2022.
  • BridgeBio Pharma's Interest & Investment Income (Quarterly) stood at $182,000 in 2021, then surged by 2,148.35% to $4.1 million in 2022, then surged by 36.31% to $5.6 million in 2023, then fell by 16.05% to $4.7 million in 2024, then skyrocketed by 89.29% to $6.2 million in 2025.
  • Its Interest & Investment Income was $6.2 million in Q3 2025, compared to $3.9 million in Q2 2025 and $5.4 million in Q1 2025.